 |
23 Diseases |  |
1 Trial |
|
1 Trial |  |
117 News |  |
| «12 |
- | Review, Journal: Current and future pharmacological therapies for NAFLD/NASH. (Pubmed Central) - Oct 9, 2019
Among a variety of medications in development, four agents such as OCA, elafibranor, ASK1 inhibitor, and CVC are currently being evaluated in an international phase 3 trial for the treatment of NASH. Within the next few years, the availability of therapeutic options for NASH will hopefully curb the rising trend of NASH-related diseases.
- Aramchol (arachidyl amido cholanoic acid) / Galmed Medical Research, Weizmann Institute of Science
ARAMCHOL, SCD1 INHIBITOR, IMPROVES LIVER GLUCOSE HOMEOSTASIS IN NASH (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2898;
These results suggest that Aramchol targets not only the alterations in lipid metabolism that characterize NASH but additionally improves liver glucose homeostasis in patients and murine models. Also, in Aramchol-treated primary hepatocytes, there is an inhibition in LPC and GPC formation, which would improve VLDL-TG secretion, together with a reduction in TCA cycle metabolites.
- Aramchol (arachidyl amido cholanoic acid) / Galmed Medical Research, Weizmann Institute of Science
INCREASED EXPOSURE OF ARAMCHOL BY USING A SPLIT DOSE – POTENTIAL FOR GREATER EFFICACY IN NASH (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1901;
The prediction from the PK model was born out with substantially higher concentrations of Aramchol obtained with twice daily regimen. Based on the ARREST study and dose dependency pattern, this increase in exposure offers the potential for greater efficacy in the treatment of NASH with Aramchol.
- | Aramchol (aramchol meglumine) / Galmed
New P3 trial: A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) (clinicaltrials.gov) - Sep 25, 2019
P3, N=2000, Recruiting, Sponsor: Galmed Research and Development, Ltd.
- || Aramchol (aramchol meglumine) / Galmed
Trial completion: Comparison of Aramchol Concentrations With Once or Twice Daily Dosing (clinicaltrials.gov) - Apr 4, 2019
P1, N=16, Completed, Sponsor: Galmed Pharmaceuticals Ltd
Based on the ARREST study and dose dependency pattern, this increase in exposure offers the potential for greater efficacy in the treatment of NASH with Aramchol. Recruiting --> Completed
- || Aramchol (aramchol meglumine) / Galmed
Trial completion: Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers (clinicaltrials.gov) - Apr 4, 2019
P1, N=15, Completed, Sponsor: Galmed Pharmaceuticals Ltd
Recruiting --> Completed Active, not recruiting --> Completed
- || Aramchol (aramchol meglumine) / Galmed
Enrollment open: Comparison of Aramchol Concentrations With Once or Twice Daily Dosing (clinicaltrials.gov) - Jan 2, 2019
P1, N=16, Recruiting, Sponsor: Galmed Pharmaceuticals Ltd
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Aramchol (aramchol meglumine) / Galmed
New P1 trial: Comparison of Aramchol Concentrations With Once or Twice Daily Dosing (clinicaltrials.gov) - Dec 11, 2018
P1, N=16, Not yet recruiting, Sponsor: Galmed Pharmaceuticals Ltd
- | Aramchol (aramchol meglumine) / Galmed
New P1 trial: Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers (clinicaltrials.gov) - Nov 29, 2018
P1, N=16, Active, not recruiting, Sponsor: Galmed Pharmaceuticals Ltd
- |||| Aramchol (aramchol meglumine) / Galmed
Trial completion: ARREST: A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH (clinicaltrials.gov) - Jun 26, 2018
P2b, N=247, Completed, Sponsor: Galmed Pharmaceuticals Ltd
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Aramchol (aramchol meglumine) / Galmed
Trial completion, Trial completion date: ARRIVE: Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy (clinicaltrials.gov) - Jun 13, 2018
P2, N=50, Completed, Sponsor: University of California, San Diego
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Jan 2020 --> Feb 2018
- ||| Aramchol (aramchol meglumine) / Galmed
Enrollment closed: ARREST: A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH (clinicaltrials.gov) - Jan 26, 2017
P2b, N=240, Active, not recruiting, Sponsor: Galmed Pharmaceuticals Ltd
Recruiting --> Completed | Trial completion date: Jan 2020 --> Feb 2018 Recruiting --> Active, not recruiting
- ||| Aramchol (aramchol meglumine) / Galmed
Trial completion: Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers (clinicaltrials.gov) - Dec 21, 2016
P1, N=64, Completed, Sponsor: Galmed Pharmaceuticals Ltd
Recruiting --> Active, not recruiting Recruiting --> Completed
- || Aramchol (aramchol meglumine) / Galmed
Trial primary completion date: ARREST: A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH (clinicaltrials.gov) - Jun 22, 2016
P2b, N=240, Recruiting, Sponsor: Galmed Pharmaceuticals Ltd
Recruiting --> Completed Trial primary completion date: Mar 2017 --> Mar 2018
- ||| Aramchol (aramchol meglumine) / Galmed
New P1 trial: Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers (clinicaltrials.gov) - Jun 18, 2016
P1, N=64, Recruiting, Sponsor: Galmed Pharmaceuticals Ltd
- Aramchol (aramchol meglumine) / Galmed
New P2 trial: ARRIVE: Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy (clinicaltrials.gov) - Feb 18, 2016
P2, N=50, Recruiting, Sponsor: University of California, San Diego
- || Aramchol (aramchol meglumine) / Galmed
Trial primary completion date: ARREST: A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH (clinicaltrials.gov) - Nov 5, 2015
P2b, N=240, Recruiting, Sponsor: Galmed Pharmaceuticals Ltd
Trial primary completion date: Mar 2017 --> Mar 2018 Trial primary completion date: Aug 2016 --> Mar 2017
- Aramchol (aramchol meglumine) / Galmed
Enrollment change, Trial termination, Trial primary completion date: Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study (clinicaltrials.gov) - Oct 5, 2015
P2a, N=10, Terminated, Sponsor: Galmed Pharmaceuticals Ltd
Trial primary completion date: Aug 2016 --> Mar 2017 N=36 --> 10 | Recruiting --> Terminated | Trial primary completion date: Apr 2015 --> Oct 2015; Protocol redesign
- Aramchol (aramchol meglumine) / Galmed
New P1 trial: Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers (clinicaltrials.gov) - Feb 27, 2015
P1, N=66, Completed, Sponsor: Galmed Pharmaceuticals Ltd
- |||| Aramchol (aramchol meglumine) / Galmed
Enrollment open: ARREST: A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH (clinicaltrials.gov) - Feb 10, 2015
P2b, N=240, Recruiting, Sponsor: Galmed Pharmaceuticals Ltd
N=36 --> 10 | Recruiting --> Terminated | Trial primary completion date: Apr 2015 --> Oct 2015; Protocol redesign Not yet recruiting --> Recruiting
- Aramchol (aramchol meglumine) / Galmed
New P2a trial: Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study (clinicaltrials.gov) - Dec 29, 2014
P2a, N=36, Recruiting, Sponsor: Galmed Pharmaceuticals Ltd
- |||||| Aramchol (aramchol meglumine) / Galmed
New P2b trial: ARREST: A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH (clinicaltrials.gov) - Oct 31, 2014
P2b, N=240, Not yet recruiting, Sponsor: Galmed Pharmaceuticals Ltd
- |||| Aramchol (aramchol meglumine) / Galmed
Trial completion: Aramchol003: Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis (clinicaltrials.gov) - Jan 29, 2012
P2, N=60, Completed, Sponsor: Galmed Medical Reserch
Not yet recruiting --> Recruiting Recruiting --> Completed